Allogene Therapeutics : ALLO January 2022 Corporate Presentation

The Next Revolution in Cell Therapy

Leading Today, Defining Tomorrow

January 2022

Legal Disclaimers

To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: clinical outcomes, which may materially change as more patient data become available; the timing and ability to progress clinical trials, including the timing and ability to progress to a Phase 2 clinical trial of ALLO-501A; the ability to manufacture AlloCAR T™ therapies for use in clinical trials; the results of the clinical hold investigation; the potential of next-generation technology, such as TurboCAR™; and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended September 30, 2021.

Caution should be exercised when interpreting results from separate trials involving separate product candidates. There are differences in the clinical trial design, patient populations, follow-up times, and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

2

Allogene: Creating the Allogeneic Cell Therapy Playbook

4 Foundational platform technologies

• AlloCAR TTM

• TurboCARTM

• iPSC

• Allogeneic manufacturing

~300

employees

defining the field and writing the

allogeneic CAR T playbook

130	more patients treated
>	with AlloCAR TTM
product candidates
than any other
Patients	allogeneic CAR T
treated

$862

million

in cash, cash equivalents and investments as of Sept 30, 2021

singular focus on allogeneic cell therapy

Fully Integrated Research, Process Development, Clinical, Translational Science and Manufacturing Capabilities

3

Allogeneic CAR T Value Proposition: From Process to Product

Today, CAR T is a procedure…

…Tomorrow, CAR T could be a biopharmaceutical product

Access	Speed &	Manufacturing
	Reliability	Cost

* Option for additional dose

4

Industrializing Allogeneic Cell Therapy Production

Strength in Manufacturing Capability

• Our state-of-the-art manufacturing facility, Cell Forge 1, operational and producing GMP material
• Designed to be scalable and ready for commercialization

Strength in Product Quality

• Understanding product quality is a cornerstone objective
• Managed by specially created Attribute Science teams working with QC teams

Strength in Network Coordination

• Building Supply Chain network and relationship to enable inflow of complex starting material to Cell Forge 1.
• Coordinating complex logistics to ensure the flow of drug product out of Cell Forge 1 to clinical sites

5